Campath-1H therapy in refractory ocular inflammatory disease.
BACKGROUND
Standard therapy for severe, immune mediated, ocular inflammation has significant side effects, and may fail to control the disease. T cell directed monoclonal antibody (mAb) therapy can provide long term remission of inflammatory disease in experimental models. The Campath-1H mAb was administered to patients with severe, refractory, ocular inflammation.


METHODS
10 patients with severe, refractory, non-infectious ocular inflammatory disease were treated with Campath-1H mAb. This is a fully humanised mAb which recognises the pan-lymphocyte antigen CD52.


CONCLUSIONS
Following Campath-1H therapy, all 10 patients showed an initial resolution of their ocular symptoms and signs. Long lasting remissions were achieved in eight patients, in whom baseline immunosuppression could subsequently be reduced to minimal levels. The possible mechanisms of action of Campath-1H therapy are discussed.
Dick
A D
AD
Department of Ophthalmology, University of Aberdeen Medical School.
Meyer
P
P
James
T
T
Forrester
J V
JV
Hale
G
G
Waldmann
H
H
Isaacs
J D
JD
D000328:Adult; D000368:Aged; D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000627:therapeutic use*; D001327:Autoimmune Diseases / Q000276:immunology / Q000628:therapy*; D016039:Corneal Transplantation; D003930:Diabetic Retinopathy / Q000628:therapy; D005128:Eye Diseases / Q000276:immunology / Q000628:therapy*; D005500:Follow-Up Studies; D005901:Glaucoma / Q000628:therapy; D006084:Graft Rejection / Q000628:therapy; D014890:Granulomatosis with Polyangiitis / Q000628:therapy; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods*; D008875:Middle Aged; D012164:Retinal Diseases / Q000628:therapy; D014657:Vasculitis / Q000628:therapy
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D000074323:Alemtuzumab